Please login to the form below
Merck and Co/MSD
This page shows the latest Merck and Co/MSD news and features for those working in and with pharma, biotech and healthcare.
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
Combination treatment topped Pfizer's Sutent in phase 3. Merck &Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in ... According to Merck and Eisai, when administered alongside Lenvima,
Latest news
-
AZ’s comeback drug cediranib stumbles in phase 3 trial
The National Cancer Institute-sponsored GY004 study compared cediranib plus AZ and Merck &Co/MSD's leading PARP inhibitor Lynparza (olaparib) against chemo in patients with platinum-sensitive ovarian cancer, but ... and cervical cancer indications,
-
Roche files Tecentriq/Avastin combo in liver cancer
Its combination with Avastin is viewed as a central part of its strategy to gain ground on the leaders in the category, such as Merck &Co/MSD’s Keytruda (pembrolizumab) and ... Tecentriq has carved out a nice for itself in indications including
-
FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
t have EGFR or ALK mutations, and is due to deliver a verdict by 15 May. ... If approved, BMS will finally have a regimen that can challenge its main rival in the PD-1 inhibitor category – Merck &Co/MSD and its Keytruda (pembrolizumab) product –
-
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer
AZ/Merck look set to consolidate dominance in this indication. AstraZeneca and Merck &Co/MSD’s PARP inhibitor looks set to consolidate its grip on the ovarian cancer market, after being ... Lynparza has been the dominant drug in the PARP inhibitor
-
AZ, Merck win FDA approval for Lynparza in pancreatic cancer
New treatment option for subset of patients with BRCA-mutations. AstraZeneca and partner Merck &Co/MSD can now add pancreatic cancer to the growing list of cancers targeted by their PARP ... The approval will help AZ and Merck to maintain a lead over
More from news
Approximately 0 fully matching, plus 54 partially matching documents found.
Latest Intelligence
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Merck KGaA’s Oschmann elected president of IFPMA
He takes over from Lilly’s John Lechleiter. Global pharma trade body the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has elected Merck KGaA's Stefan Oschmann as its new ... His pharma experience includes an 11-year
-
Merck KGaA shakes up pharma leadership
Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ... Oschmann also joined Merck in 2011, having spent the
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
